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Abstract 
We aimed to demonstrate the existence of cancer stem cells in human pancreatic cancer, 
and to clarify that they are alpha-fetoprotein (AFP) producing cells. Six cell lines derived from 
human pancreatic cancers were examined, and AsPC-1 and PANC-1 were noted to express AFP. 
Single cell culture assays and xenotransplantation revealed that the AFP-producing cells had the 
capacity for self-renewal and differentiation, and that these cells were tumorigenic. Furthermore, 
they were resistant to anti-cancer agents. The ABCA12 transporter was expressed in the 
AFP-producing cells at a level more than twice as high as that in the non-AFP-producing cells. 
The AFP-producing cells were shown to be putative pancreatic cancer stem cells. 
Furthermore, the expression of ABCA12 appears to be associated with drug resistance.  
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1. Introduction 
Recent advances in stem cell biology have revealed the existence of cancer stem cells 
(CSCs) in various tumors, including leukemia [1], breast cancer [2], brain tumor [3] and pancreatic 
cancer [4, 5]. CSCs are defined as cells that possess the capacity to self-renew, to cause the 
heterogeneous population of cancer cells, and to initiate tumors [6]. In addition, CSCs are 
supposed to have long lifetime and show drug- and/or radiation-resistance, like normal tissue stem 
cells. These properties of the CSCs might contribute to the tumor malignancy such as rapid growth, 
resistance to therapy, and recurrence. Therefore, CSCs could be a new target for cancer therapies.  
To investigate the characteristics of the CSCs, it is necessary to be able to successfully 
isolate them from the heterogeneous tumor cells. There have been several reports about the 
combinations of cell surface markers that can be used to isolate the CSCs from the pancreatic 
cancer tissues [4, 5]. However, the functions and biological relevance of the individual markers in 
the tumor tissues are still unknown.  
Previously, we reported the existence of CSCs in cholangiocellular carcinoma, and 
demonstrated that these cells were as the alpha-fetoprotein (AFP) producing cells [7]. AFP is one 
of the major serum proteins produced by fetal hepatoblasts. In this study, we also focused on AFP 
as a human pancreatic cancer stem cell marker. AFP is secreted not only by the fetal liver, but also 
by foregut endoderm and fetal pancreas [8]. Because CSCs show several similarities to normal 
tissue stem cells, we hypothesized that AFP might be expressed in human pancreatic CSCs.  
2. Materials and methods 
2.1. Patients 
Twenty-five patients with pathologically-confirmed pancreatic cancer who had undergone 
a pancreatic resection at Kyoto University Hospital in 2008, were included in this study. The 
patients included 10 males and 15 females, with a mean age at surgery of 66.7 ± 7.5 years (range, 
49-77 years). Written informed consent for the use of their resected tissues was obtained from all 
patients in accordance with the Declaration of Helsinki. Their clinicopathological background is 
summarized in Supplemental Table 1. 
 
2.2. Generation of transgenic cell lines derived from human pancreatic cancer cells 
MIAPaCa-2, AsPC-1 and PANC-1 cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA), SUIT-2 was from the Health Science Research Resources Bank 
(Osaka, Japan), and KP-1NL and QGP-1 were from the Japanese Collection of Research 
Bioresources cell bank (Osaka, Japan). These cells were plated on cell culture dishes (BD 
Biosciences, Franklin Lakes, NJ), and all six cell lines were maintained in RPMI 1640 medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal calf serum (FCS; ICN 
Biomedicals Inc., Aurora, OH), 100 U/ml penicillin (Meiji Seika, Tokyo, Japan), and 100 g/ml 
streptomycin (Meiji Seika) at 37°C in a humidified atmosphere with 5% carbon dioxide. 
The transgene plasmid vectors that expressed enhanced green fluorescent protein (EGFP) 
under the control of human AFP enhancer/promoter were generated as described previously [9]. 
The transgenic vectors were transfected using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer's protocol. Stably transfected cells were selected in the presence of 800 g/ml G418 
(Sigma, St Louis, MO) over a period of 30 days. The proper transgene insertion was confirmed by 
polymerase chain reaction (PCR). The stable transfectants were cultured in the presence of 800 
g/ml G418. 
 
2.3. Reverse transcription-PCR (RT-PCR) 
RT-PCR was performed as described previously [9]. Primers were generated for the 
following human genes; EGFP, AFP, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Their sequences and the PCR conditions are summarized in Supplemental Table 2. 
 
2.4. Immunocytochemistry of cultured cells 
The cultured cells were fixed and stained as previously described [9, 10, 11]. An 
anti-human AFP rabbit antibody (DakoCytomation, Glostrup, Denmark) diluted at 1:200 was used 
as the primary antibody, and Alexa546-conjugated donkey anti-rabbit IgG (Molecular Probes, 
Eugene, OR) diluted at 1:500 was used as the secondary antibody. The stained cells were covered 
with Vectashield mounting medium with 4',6-diamidino-2-phenylindole (DAPI; Vector 
Laboratories, Burlingame, CA).  
 
2.5. Histology and immunohistology 
The harvested tumors were fixed in 3.3% formaldehyde (Wako, Osaka, Japan) for at least 
one week. After a thorough rinsing, the tissues were then embedded in paraffin and sectioned into 
3 m thick sections. Hematoxylin-eosin (HE) staining was performed according to a standard 
protocol. In order to perform immunohistological staining for AFP, the deparaffinized and 
rehydrated sections were incubated in 3% hydrogen peroxide in methanol for 10 minutes and then 
were incubated with the diluted anti-human AFP antibodies at 4°C for 16 hours. Followed by 
thorough rinsing, the samples were incubated for 30 minutes with horseradish 
peroxidase-conjugated anti-rabbit IgG (Envision+ Kit/horseradish peroxidase; DakoCytomation) 
and then for 1 minute with 3,3'-Diaminobenzidine (DAB) substrates (DakoCytomation). 
Counterstaining was performed using hematoxylin.  
 
2.6. Flow cytometry 
The cultured cells were prepared as described previously [9, 10, 11]. Dead cells were 
eliminated using 7-amino-actinomysin D (7-AAD; BECKMAN COULTER, Brea, CA). The cells 
were analyzed and isolated using a FACSVantage SE cell sorter (BD Biosciences).  
For the single-cell culture analyses, individual isolated cells were inoculated into each 
well of 96-well culture plates using the FACSVantage SE and the CloneCyt Plus software program 
(BD Biosciences). That the wells contained only one cell was confirmed using a light microscope 
10 to 16 hours after cell sorting. Following cell expansion after isolation of each clone, they were 
subjected to flow cytometry as described previously. 
 2.7. Cell proliferation assay and anchorage-independent growth assay 
The isolated EGFP-positive and EGFP-negative cells were inoculated at a density of 1 
103 cells per well in 96-well culture plates (BD Biosciences), and then were allowed to grow for 
eight days. The cell numbers were determined using the 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazorium, 
inner salt (MTS) assay (Cell Titer 96 Aqueous One Solution Reagent; Promega, Madison, WI), 
according to the manufacturer's protocol. After a 1 hr of incubation, the absorbance value was 
measured using a plate reader at 490 nm. 
To examine the anchorage-independent growth of the cells, 1 104 EGFP-positive and 
EGFP-negative cells were suspended in 2.0 ml of 0.3% agar (Wako) supplemented with the culture 
medium. The cell suspension was layered over the bottom layer of 2.0 ml of 0.6% agar. The 
AsPC-1 colonies that contained more than 10 cells were counted 21 days after cell sorting, and the 
colonies of PANC-1 cells were counted 7 days after sorting. 
 
2.8. Xenotransplantation  
Male 8 to 12-week-old non-obese diabetic/severe combined immune deficiency 
(NOD/SCID) mice (CLEA Japan, Inc., Tokyo, Japan) were utilized in the transplantation 
experiments. The sorted cells were washed twice with PBS after flow cytometry, and resuspended 
in 200 µl of a serum-free medium and Matrigel (BD Biosciences) mixture (1:1 volume). Under 
general anesthesia, the cells were engrafted into the right and left dorsal areas of NOD/SCID mice 
subcutaneously using a 26-gauge needle. During the following 12 weeks, mice were examined 
periodically by visual inspection and palpation, and then they were sacrificed to extract tumors.  
To investigate the composition of the tumors grown in NOD/SCID mice, serial 
transplantation was performed. The tumors that were generated from the single-cell-derived 
EGFP-positive or EGFP-negative cells were harvested. The tumor tissues were cut into small 
pieces by using sterile blades, and were digested with collagenase solution [12] for 60 minutes at 
37°C. After rinsing twice with PBS, the cells were analyzed using a FACSCalibur (BD 
Biosciences), or sorted using a FACSVantage SE. For secondary xenotransplantation, the harvested 
cells were cultured in G418-containing medium for at least 7 days to eliminate cells originated 
from the host mice. Thereafter, these cells were sorted according to the EGFP fluorescence, and 
then 5 104 cells of the EGFP-positive or EGFP-negative fractions were transplanted into 
NOD/SCID mice. 
All experimental procedures utilizing animals were performed in accordance with the 
Animal Protection Guidelines of Kyoto University. 
 
2.9. Drug resistance assay 
To investigate the resistance of the cells to anticancer agents; 5-fluorouracil (5-FU; 
WAKO) and gemcitabine (GEM; WAKO) were added to the cultures of the EGFP-positive and 
EGFP-negative cells for 4 days in the presence of the anticancer agents at various concentrations 
(from 1 10-12M to 1 10-4M). To determine the half-maximal effective concentration (EC50) of 
these agents, MTS assays were performed after the 4 day-culture in the presence of these 
anticancer agents at various concentrations. The proportions of the EGFP-positive cells were 
analyzed with a FACSCalibur.  
 
2.10. Quantitative PCR (qPCR) 
The total RNA was extracted from the freshly sorted EGFP-positive and EGFP-negative 
cells of the AsPC-1 or PANC-1 cell lines, using an RNeasy Mini Kit (Qiagen, Chatsworth, CA) 
and treated with RNase-free DNase (Qiagen). The total RNA (0.5 g) was reverse-transcribed into 
cDNA using the RT2 First Strand Kit (SABiosciences, Frederick, MD) according to the 
manufacture’s protocol. The qPCR assays were performed on an ABI 7500 (Applied Biosystems, 
Foster City, CA) using the Human Drug Transporters RT2 Profiler PCR Array and RT
2
 SYBR 
Green Master Mix (SABiosciences) according to the manufacture’s protocol. The differences in 
mRNA expression between the EGFP-positive and EGFP-negative cells was calculated based on 
the DDCt method. Results were obtained from three independent trials. 
 
2.11. Statistical analysis 
All experiments were performed at least three times. The results are given as the means ± SD. The 
statistical analyses were performed using Student’s t-test, Dunnett’s multiple comparisons and 
repeated-measures analyses of variances (ANOVA). P < 0.05 was considered to be statistically 
significant. All statistical tests were two-sided. 
 
  
3. Results 
3.1. Generation of transgenic pancreatic cancer cell lines 
RT-PCR revealed that AFP expression was observed in both the AsPC-1 and PANC-1 cell 
lines (Fig. 1A). The AFP-EGFP reporter vector was transfected into the six human pancreatic 
cancer cell lines. Only the AsPC-1 and PANC-1 cells exhibited EGFP fluorescence with 
fluorescent microscopy (Fig. 1B, C); the other four cell lines did not, despite the fact that they 
possessed the transgene in their genomic DNA (data not shown). The AsPC-1 cell line is derived 
from the ascites of a pancreatic adenocarcinoma patient [13], and the PANC-1 line is from a 
pancreatic carcinoma of ductal origin [14]. A flow cytometric analysis showed that 25.1 ± 1.1% 
(n=3) of the AsPC-1 cells and 6.5 ± 1.1% (n=3) of the PANC-1 cells expressed the EGFP 
fluorescence (Fig. 1D, E). The sorted EGFP-positive cells expressed both EGFP and AFP mRNA, 
whereas the sorted EGFP-negative cells did not express either molecule (Fig. 1F), thus indicating 
that the EGFP-positive cells to correspond to the AFP-producing cells, and that cell sorting could 
be used to divide these cells according to their EGFP expression. Therefore, a further investigation 
of the AFP-producing cells in the both cell lines was conducted to determine whether or not they 
were pancreatic CSCs.  
 
3.2. Single cell sorting and culture assay 
Since these cell lines were heterogeneous populations, single-cell culture assays were 
performed in order to examine their self-renewal and differentiation capabilities. A single cell was 
sorted and cultured in a well of a 96-well culture plate. Following cell expansion by four passages, 
flow cytometric analyses were performed. A single EGFP-positive cell generated both  
EGFP-positive and EGFP-negative cell fractions (Figs. 2A, B, E, F). One EGFP-negative cell, 
however, produced only the EGFP-negative fraction (Figs. 2C, D, G, H). These flow cytometric 
findings were reproducible in three trials (four EGFP-positive clones and five EGFP-negative 
clones were obtained from AsPC-1, and twelve EGFP-positive and twelve EGFP-negative clones 
from PANC-1), and the transgene was identified in the genomic DNA of all these clones 
(Supplemental Figure 1). These results indicated that the EGFP-positive cells had the ability to 
self-renew and the ability to generate the EGFP-negative cell fraction. These results also suggested 
that the AFP-producing cells of both cell lines had progenitor-like characteristics. 
 
3.3. In vitro cell proliferation assay 
To compare the in vitro tumorigenicity between the EGFP-positive and EGFP-negative 
cells, cell proliferation and the anchorage-independent cell growth assays were performed. In both 
cell lines, the EGFP-positive cells exhibited significantly higher proliferation than did the 
EGFP-negative cells (P<0.05, n=3; Fig. 3A, B). Moreover, the EGFP-positive cells showed 
stronger colony-forming abilities (approximately 2.5-fold in AsPC-1 and 4-fold in PANC-1) in soft 
agar than the EGFP-negative cells did (*P<0.005, **P<0.001, n=3; Fig. 3C, D). These findings 
suggest that the EGFP-positive cells have stronger tumorigenic and malignant potentials in vitro 
than do the EGFP-negative cells. 
 3.4. Xenotransplantation into immunodeficient mice 
To examine the tumorigenicity in vivo, the EGFP-positive or EGFP-negative cells were 
transplanted subcutaneously into the backs of NOD/SCID mice. A total of 10,000 to 500 cells and 
the mice were observed for 12 weeks. Both the EGFP-positive and EGFP-negative cells formed 
tumors in NOD/SCID mice. There were no differences in the proportion of tumor formation, or the 
time until tumor detection between the EGFP-positive and EGFP-negative cells in the both cell 
lines (Supplemental Table 3). 
To further examine the characteristics of the cellular differentiation potential in vivo, serial 
transplantation was performed. The EGFP-positive clones derived from the single-cell cultures 
were used as donor cells (Fig. 4A, G). The EGFP-positive and EGFP-negative fractions were 
isolated before the primary transplantation (Fig. 4B, H). In both cell lines, the tumors derived from 
the xenotransplantation of the EGFP-positive cells had both EGFP-positive and EGFP-negative 
cell fractions (Fig. 4D, J). In contrast, the tumors from the EGFP-negative cells generated only the 
EGFP-negative fraction (Fig. 4C, I). These results demonstrated the self-renewal and 
differentiation abilities of the EGFP-positive cells in vivo. Furthermore, the EGFP-positive and 
EGFP-negative cells isolated from the EGFP-positive cell-derived tumors were transplanted again 
at 5 104 cells into NOD/SCID mice. Both cell lines formed tumors. The tumors from the 
EGFP-positive cells had both the EGFP-positive and EGFP-negative cell fractions (Fig. 4F, L), 
and the tumors from the EGFP-negative cells had only EGFP-negative fraction (Fig. 4E, K). These 
results indicated that the EGFP-positive cells kept their self-renewal potential and ability to 
differentiate through several passages in vivo. 
 
3.5. Drug resistance assay 
The resistance of the two cell lines to 5-FU and GEM was examined. EC50values were 
calculated based on MTS assays, showing that the EC50 values for 5-FU were 5.15 × 10
-6
 M for 
AsPC-1 and 1.03 × 10
-6
 M for PANC-1, respectively. Those for GEM were 5.48 × 10
-10
 M for 
AsPC-1 and 4.54 × 10
-8
 M for PANC-1. In both cell lines, the proportions of the EGFP-positive 
cells increased when the whole cell populations were cultured in the presence of these anticancer 
agents around the EC50 (Fig. 5A-D). The number of total living cells was decreased at 
concentrations over the EC50. It was demonstrated that the EGFP-positive cells in both cell lines 
had greater drug resistance against both 5-FU and GEM. 
In order to examine the mechanism responsible for the drug resistance, the expression 
levels of mRNA related to drug transporters that move cytotoxic substances outside the cell 
membrane were compared between the AFP-producing cells and the non-AFP-producing cells by 
qPCR assays. The ABCB1 transporter in AsPC-1 cells, and the ABCB4 transporter in PANC-1 
cells, which are known multidrug resistance transporters, were expressed in the EGFP-positive 
cells at more than twice the levels as that in the EGFP-negative cells. In both cell lines, the 
ABCA12 transporter was highly expressed in the EGFP-positive cells (Fig. 5E-H).  
 
3.6. Histology and immunohistology of surgical specimens 
In order to examine the AFP expression in human clinical pancreatic cancer, immunohistological 
assays were performed utilizing 25 surgical samples. A small number of tumor cells (less than 5%) 
expressed AFP in 16 of the 25 patients with pancreatic cancer (Figure 6, A-C). However there 
were no AFP expressing cells in any of the examined sections of the other 9 patients (Figure 6D). 
The preoperative serum AFP values were below the normal range in patients who were examined. 
The patients’ clinical background and tumor pathological features did not correlate with the AFP 
expression (Supplemental Table 1). 
 
  
4. Discussion 
CSCs are thought to have many similarities to normal tissue stem cells, and are defined by 
their ability to self-renew, to generate heterogeneous lineages of cancer cells, and to initiate tumor 
growth [6]. Although many previous reports concerning the identification of CSCs used 
combinations of cell surface markers, we focused on AFP as a marker for pancreatic CSCs. AFP is 
produced by the foregut endoderm and its derivatives; the fetal liver and pancreas during the 
embryonic period [8]. Therefore, we hypothesized that pancreatic CSCs might express AFP if the 
CSCs existed in the pancreatic cancer tissues.  
In this study, we transfected a plasmid vector that expressed EGFP under the control of 
the AFP enhancer/promoter into the six human pancreatic cancer cell lines, in order to isolate and 
characterize the AFP-producing cells. AFP-producing cells were found in two of the six cell lines 
(AsPC-1 and PANC-1). The AFP-producing cells in both cell lines were demonstrated to have the 
capacity for self-renewal and differentiation to generate an non-AFP-producing cell fraction in 
vitro and in vivo, whereas the non-AFP-producing cells did not possess these characteristics. The 
AFP-producing cells were also shown to have a higher proliferation activity in vitro and 
tumorigenicity in vivo. These results indicated that the AFP-producing cells corresponded to 
cancer progenitor cells in pancreatic cancer. The non-AFP-producing cells had the same 
tumorigenicity as the AFP-producing cells in vivo. This was probably because the tumor cell lines 
had, in general, a higher malignant potential than their original tumor tissues [15]. However, the 
non-AFP-producing cells did not generate heterogeneity concerning EGFP expression in the 
xenografted tumor tissues.  
The existence of the AFP-producing cells in human clinical specimens was also 
demonstrated by the immunohistological analyses. A small number of tumor cells expressed AFP 
in 16 of the 25 patients with pancreatic cancer. There have also been several reports of pancreatic 
cancers with high serum AFP levels, which tend to be associated with a worse prognosis because 
of high rates of liver metastasis [16]. These finding suggested that AFP could be a CSC marker in 
clinical cases. Although there were no patients with high preoperative serum AFP values in our 25 
cases, the AFP-producing pancreatic cancers might represent cases of abnormal proliferation or 
increased numbers of AFP-producing CSCs, which would result in a poorer prognosis.  
The CD24
+
CD44
+
epithelial specific antigen (ESA)
+
 [4], CD133
+
, and CD133
+
CXCR4
+
 
cells in pancreatic cancer tissues [5] have previously been reported as pancreatic CSCs. We 
examined the relationship between the AFP expression and these reported cell surface markers. In 
the PANC-1 cells, the CD24-positive or CD133-positive cell fractions included a large part of the 
EGFP-positive cells. The AFP-producing PANC-1 cells were enriched in the CD24
+
CD133
+
 cell 
fraction, confirming that CD24 and CD133 are useful for isolating CSCs in some pancreatic 
cancers. On the other hand, the AsPC-1 cells had neither CD24-positive nor CD133-positive cell 
fractions. In addition, the expression of CD44, ESA, and CXCR4 did not correlate with the AFP 
expression in either cell line (Supplemental Figure 2). These findings suggested that there might be 
several types of CSCs in various stages of differentiation, and that the profiles of cell surface 
markers could vary among these CSCs. The CD133
+
CXCR4
+
 cells were found in the tumor 
invasive front [5], suggesting that CSCs might change their phenotype depending on their 
environment. 
AFP-producing cells were not found in all cell lines or all surgical specimens. These 
findings raise the question whether all pancreatic cancer tissues have their own CSCs. Furthermore, 
it remains unclear whether all pancreatic CSCs have a common marker, or whether, as mentioned 
above, different markers and phenotypes may occur depending on the microenvironment. Further 
are necessary to answer these questions. However, it would be biologically difficult to find a 
common marker for pancreatic CSCs because of the genetic instability of CSCs [17]. 
 CSCs are also assumed to contribute to chemoresistance and radioresistance. This study 
demonstrated that the AFP-producing cells in both cell lines showed resistance to 5-FU and GEM 
compared to non-AFP-producing cells. The qPCR analyses revealed that the ABCA12 gene, which 
encodes one of the ABC transporter family proteins, was highly expressed in the AFP-producing 
cells of both cell lines. The expression of ABCA12 has been reported to be predominantly found in 
the skin and the stomach. This transporter is assumed to play a role in skin lipid homeostasis, and 
is highly expressed in healthy keratinocytes. Mutations in the ABCA12 gene were detected in 
patients suffering from lamellar ichthyosis type 2 and harlequin ichthyosis, a rare hereditary 
disease characterized by skin desquamation over the whole body [18]. However, there have been 
only a few reports about ABCA12 expression in cancer. In these reports, positive correlations were 
found between the expression of ABCA12 and the resistance of breast cancer to neoadjuvant 
chemotherapy [19], and a retinoblastoma cell line was reported to highly express the ABCA12 
gene [20]. Our results suggested that the ABCA12 transporter may be associated with the 
chemoresistance of pancreatic CSCs. It has also been postulated that some CSCs are able to enter 
into the G0 phase of the cell cycle, and this characteristic is also thought to enhance their 
chemoresistance. However, the cell cycle analyses of our cell lines showed no significant 
differences in the proportions of G0 phase cells between the AFP-producing and 
non-AFP-producing cells (data not shown).  
In conclusion, the AFP-producing cells were shown to be cancer progenitor cells, or 
putative CSCs of human pancreatic cancer. In addition, the drug transporter ABCA12 was 
preferentially expressed in the AFP-producing cells, suggesting that the high expression of 
ABCA12 may be associated with the CSCs’ resistance to anti-cancer agents. AFP and ABCA12 
may represent a new prognostic marker or target for cancer therapies.  
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Legends 
 
Figure 1. 
The human pancreatic cancer cell lines that expressed EGFP under the control of the 
human AFP enhancer/promoter. (A) An RT-PCR analysis of the six pancreatic cancer cell lines. (B, 
C) The stable transfectants of AsPC-1 and PANC-1 cells expressed EGFP florescence in 
fluorescent microscopy images (right panels). The left panels show the phase contrast images of 
the same visual fields of the right panels. Original magnification: 200. (D, E) A flow cytometric 
analysis revealed the AsPC-1 and PANC-1 cells express EGFP in 25.1 ± 1.1% and 6.5 ± 1.1% of 
cells, respectively. The vertical axis indicates the 7-AAD fluorescence and the horizontal axis 
indicates the intensity of EGFP. (F) In both cell lines, the sorted EGFP-positive cells expressed 
mRNA for both EGFP and AFP (left lane), whereas the sorted EGFP-negative cells expressed 
neither EGFP nor AFP mRNA (right lane). GAPDH was used as an internal control and samples 
without reverse transcriptase (RT) served as a negative control.  
 
Figure 2. 
Single cell sorting analyses of the AFP-producing EGFP-positive cells and 
non-AFP-producing EGFP-negative cells. (A, E) The individual EGFP-positive cells were sorted 
into each well of 96 well culture plates. The single cell indicated by the circle generated both the 
EGFP-positive and EGFP-negative cell fractions (B, F). On the other hand, the single 
EGFP-negative cell (C, G) produced only the EGFP-negative cell fraction (D, H).  
 Figure 3. 
Comparison of tumorigenicity in vitro between the AFP-producing EGFP-positive and 
non-AFP-producing EGFP-negative cells. (A, B) A comparison of the MTS assays between the 
two cell populations was made using repeated-measures ANOVA (both P<0.05). (C, D) The graph 
indicates the colony numbers of the EGFP-positive and EGFP-negative cells growing in soft agar 
(Student’s t-test; *P<0.005, **P<0.001). The results are presented as the means ± SD. 
 
Figure 4. 
Flow cytometry of the serially transplanted AsPC-1 (A-F) and PANC-1 (G-L) tumors. The 
cultured AsPC-1 (A, B) and PANC-1 (G, H) cells derived from single cells were isolated according 
to their EGFP fluorescence, and transplanted into NOD/SCID mice. The tumors derived from the 
EGFP-positive (D and J) and EGFP-negative cells (C and I) were enzymatically digested and 
analyzed by flow cytometry. The EGFP-positive and EGFP-negative cells were isolated from the 
EGFP-positive cell-derived tumor (D and J), and were secondarily transplanted to the NOD/SCID 
mice. The EGFP-negative cell-derived secondary tumor had only EGFP-negative cells (E and K) 
but the EGFP-positive cell-derived tumor had both EGFP-positive and EGFP-negative components 
(F and L). 
 
Figure 5. 
The drug resistance analyses for 5-FU (A, B) and GEM (C, D). The vertical axis indicates 
the proportion of the EGFP-positive cells, and the horizontal axis indicates the concentration of the 
agent. In both cell lines, the number of EGFP-positive cells still increased when exposed to these 
drugs over the usual EC50. *P < 0.05 compared with the control in Dunnett’s multiple comparisons. 
Quantitative PCR (qPCR) arrays for drug transporters were performed (E, G). Genes that showed 
mRNA expression more than twice or less than half in the AFP-producing EGFP-positive cells 
compared to the non-AFP-producing EGFP-negative cells are shown in (F, H). In both cell lines, 
the mRNA for ABCA12 was highly expressed in the EGFP-positive cells.  
 
Figure 6.  
 The immunohistological analyses of human pancreatic cancer tissues. Figures A-C were 
obtained from samples from three different patients with AFP-expressing tumor cells, and figure D 
was from one patient without AFP-expressing cells. The left row indicates the HE staining of 
tumor tissue; the center and right rows show immunostaining for AFP. The arrowheads indicate 
the cells that express AFP. Original magnifications: the left two rows, 100×; the right row, 400×.  
 
 








Supplemental Table 1 
Age at surgery 66.7 ± 7.5
Gender
     Male 10 (6)
     Femal 15 (10)
Preoperative chemotherapy
        + 3 (2)
        − 22 (14)
Operative procedure
     Pancreatoduodenectomy 19
     Distal pancreatectomy 4
     Total pancreatectomy 2
Tumor location
     Head 20
     Body 5
     Tail 0
Tumor size (mm) 30.5 ± 15.2
Pathology
   Invasive ductal carcinoma
      -tubular adenocarcinoma
           well differentiated 5 (3)
           moderately differentia 16 (11)
      -poorly differentiated 2 (1)
      -adenosquamous carcino 1 (1)
   IPMN * 1 (0)
TNM stage
     IA 1 (0)
     IB 2 (2)
     IIA 11 (6)
     IIB 8 (5)
     III 3 (3)
     IV 0 (0)
Preoperative serum AFP (ng/ml)
     < 15 ng/ml 21 (13)
     ≥ 15 ng/ml 0 (0) 
     Unknown 4 (3)
The clinicopathological background of the patients that 
underwent pancreatic resection at Kyoto University Hosp  
in 2008. 
The numbers in parentheses indicate those of patients wi  
the AFP-producing cells in their tumor tissues.
Supplemental Table 2
PCR primer sequences and PCR conditions
Gene Symbol Forward Primer Reverse Primer Annealing Temperature PCR Cycles
AFP 5‘-GGGAGCGGCTGACATTATTA 5‘-CCCTCTTCAGCAAAGCAGAC 60°C 30
EGFP 5‘-AAGCAGCACGACTTCTTCAA 5‘-CGGCCATGATATAGACGTTG 60°C 25
GAPDH 5‘-CGAGATCCCTCCAAAATCAA 5‘-GTCTTCTGGGTGGCAGTGAT 60°C 25
GAPDH; glyceraldehyde-3-phosphate dehydrogenase
Supplemental Table 3
1 × 104 5 × 103 5 × 102
AsPC-1 EGFP + 5/6 3/3 1/3
EGFP - 5/6 3/3 0/3
PANC-1 EGFP + 4/5 8/9 3/6
EGFP - 4/6 7/9 3/6
The table shows the tumor incidence of the cell transplanted mice  
The top row indicates the cell numbers of transplantation per 
mouse. The numerators indicate the number of mice that had 
tumors, and the denominators indicate the number of mice that 
received cell transplantations. The tumorigenicity between the 
EGFP-positive and the EGFP-negative cell transplanted group wa  
analyzed using Fisher’s exact test. Although P < 0.05 was 
considered to be statistically significant, no significant difference 
was observed in the tumorigenicity between the AFP-producing 
